Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)
Yang Lu, Haiying Sun
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 23, pp. 14382-14403
Closed Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 170
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy
Xiaojing Pang, Xiujuan Liu, Yuan Liu, et al.
Molecules (2021) Vol. 26, Iss. 14, pp. 4250-4250
Open Access | Times Cited: 57
Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment
Xianbo Wu, Jie Wang, Qi Liang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113116-113116
Open Access | Times Cited: 35
Focal adhesion kinase (FAK): its structure, characteristics, and signaling in skeletal system
Yuping Huang, Junguang Liao, Rexhina Vlashi, et al.
Cellular Signalling (2023) Vol. 111, pp. 110852-110852
Closed Access | Times Cited: 21
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 8
Targeting Focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders
Xiao Wang, Na Li, Yunhe Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116678-116678
Closed Access | Times Cited: 7
Discovery of Noncovalent Diaminopyrimidine-based Inhibitors for Glioblastoma via a Dual FAK/DNA Targeting Strategy
Yi Wei, Xiaoling He, Zhiwu Long, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117288-117288
Closed Access
Focal Adhesion Regulation as a Strategy against Kidney Fibrosis
Jiwen Geng, Kaikai Zheng, Peng Wang, et al.
ACS Chemical Biology (2025)
Closed Access
Discovery of 2,4-diaminopyrimidine derivatives as potent inhibitors of FAK capable of activating the Hippo pathway for the treatment of esophageal squamous cell carcinoma
Xiao Wang, Yin-Ru Li, Ji Wu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117328-117328
Closed Access
The Development of FAK Inhibitors: A Five-Year Update
Andrea Spallarossa, Bruno Tasso, Eleonora Russo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6381-6381
Open Access | Times Cited: 33
New Insights on the Nuclear Functions and Targeting of FAK in Cancer
Silvia Pomella, Matteo Cassandri, Maria Rita Braghini, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 1998-1998
Open Access | Times Cited: 30
Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2
Meng Xie, Mengyu Sun, Xiaoyu Ji, et al.
Theranostics (2022) Vol. 12, Iss. 3, pp. 1097-1116
Open Access | Times Cited: 27
HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2
Weibo Feng, Jie Chen, Wenjie Huang, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4042-4058
Open Access | Times Cited: 15
FAK-LINC01089 negative regulatory loop controls chemoresistance and progression of small cell lung cancer
Xianteng Wang, Xingkai Li, Liman Niu, et al.
Oncogene (2024) Vol. 43, Iss. 22, pp. 1669-1687
Closed Access | Times Cited: 5
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study
Jiaming Gao, Jingwen Cheng, Wanyu Xie, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 639-651
Closed Access | Times Cited: 4
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Chao Wang, Yujing Zhang, Jie Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113906-113906
Closed Access | Times Cited: 37
Targeting Protein Kinases Degradation by PROTACs
Fei Yu, Ming Cai, Liang Shao, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 35
Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy
Xiujuan Liu, Xu-Liu, Xiaojing Pang, et al.
Bioorganic & Medicinal Chemistry (2021) Vol. 47, pp. 116358-116358
Closed Access | Times Cited: 32
Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer
Jinlin Zhang, Kang Xu, Fei Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 250, pp. 115192-115192
Closed Access | Times Cited: 12
Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies
Marwa A. Fouad, Alaa A. Osman, Noha M. Abdelhamid, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles
Muhamad Mustafa, Amer Ali Abd El‐Hafeez, Dalia Abdelhamid, et al.
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113569-113569
Open Access | Times Cited: 30
Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton
Muhamad Mustafa, Gamal El‐Din A. Abuo‐Rahma, Amer Ali Abd El‐Hafeez, et al.
Bioorganic & Medicinal Chemistry Letters (2021) Vol. 40, pp. 127965-127965
Open Access | Times Cited: 26
PROTAC: targeted drug strategy. Principles and limitations
O. A. Koroleva, Yu. V. Dutikova, A.V. Trubnikov, et al.
Russian Chemical Bulletin (2022) Vol. 71, Iss. 11, pp. 2310-2334
Open Access | Times Cited: 20
Design, Synthesis and Antitumor Activity of FAK/PLK1 Dual Inhibitors with Quinazolinone as the Skeleton
Juan Sun, Ze‐Yu Fang, Yi‐Nuo Tao, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 4
Closed Access | Times Cited: 9
Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3
Hanna Cho, Injae Shin, Hojong Yoon, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 11934-11957
Closed Access | Times Cited: 23
Page 1 - Next Page

Scroll to top